Results 171 to 180 of about 20,646 (210)
Annals of Oncology, 2021 Background: Late recurrences in postmenopausal women with hormone receptor-positive breast cancers remain an important challenge. Avoidance or delayed development of resistance represents the main objective in extended endocrine therapy (ET).
G Jerusalem, Stefan Aebi, P Karlsson
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Opinion on Drug Metabolism & Toxicology, 2010
Aromatase is an enzyme which converts adrenal androgens to estrogens in postmenopausal women. Given the importance of estrogens in breast cancer growth, aromatase inhibitors are used to treat breast cancer in different settings. This review focuses on letrozole, a third generation aromatase inhibitor, encompassing pharmacodynamic and pharmacokinetic ...
Silvia, Dellapasqua, Marco, Colleoni
openaire +3 more sources
Aromatase is an enzyme which converts adrenal androgens to estrogens in postmenopausal women. Given the importance of estrogens in breast cancer growth, aromatase inhibitors are used to treat breast cancer in different settings. This review focuses on letrozole, a third generation aromatase inhibitor, encompassing pharmacodynamic and pharmacokinetic ...
Silvia, Dellapasqua, Marco, Colleoni
openaire +3 more sources
The Journal of Steroid Biochemistry and Molecular Biology, 2003
Recent clinical trials indicate that the third-generation aromatase inhibitors may be more effective than tamoxifen as first line endocrine therapy in ER+ metastatic breast cancer in postmenopausal women. This review will focus exclusively on the pharmacology of the non-steroidal inhibitor letrozole.
B P, Haynes +4 more
openaire +2 more sources
Recent clinical trials indicate that the third-generation aromatase inhibitors may be more effective than tamoxifen as first line endocrine therapy in ER+ metastatic breast cancer in postmenopausal women. This review will focus exclusively on the pharmacology of the non-steroidal inhibitor letrozole.
B P, Haynes +4 more
openaire +2 more sources
Breast, 2010 Cognitive function in postmenopausal women receiving letrozole or tamoxifen as adjuvant endocrine treatment was compared during the fifth year of treatment in a substudy of the BIG 1-98 trial.
Kelly-Anne Phillips +2 more
exaly +2 more sources